Trial Profile
An Open-label Extension Study to Evaluate the Safety and Efficacy of Subcutaneous Injections of Pegvaliase (> 40 mg/Day Dose) in Adults With Phenylketonuria
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 21 Feb 2022
Price :
$35
*
At a glance
- Drugs Pegvaliase (Primary)
- Indications Phenylketonuria
- Focus Adverse reactions; Therapeutic Use
- Sponsors BioMarin Pharmaceutical
- 02 Feb 2021 Status changed from active, no longer recruiting to completed.
- 17 Dec 2019 Planned End Date changed from 31 Dec 2019 to 31 Dec 2020.
- 17 Dec 2019 Planned primary completion date changed from 31 Dec 2019 to 31 Dec 2020.